Thu, Apr 17, 2014, 1:07 AM EDT - U.S. Markets open in 8 hrs 23 mins

Recent

% | $
Quotes you view appear here for quick access.

Medical Marijuana, Inc. Message Board

  • gooforitt gooforitt Sep 18, 2013 12:54 PM Flag

    Part 1...U.S. Patent 6630507

    http://en.wikipedia.org/wiki/Cannabidiol#Legal_status

    Legal status

    Cannabidiol is not scheduled by the Convention on Psychotropic Substances.

    Cannabidiol is a Schedule II drug in Canada.[60]

    The legal status of cannabidiol in United States is unclear. In Schedule I[61][62] there is a broad category called "Tetrahydrocannabinols", although cannabidiol is not chemically a tetrahydrocannabinol. Cannabidiol has DEA statistical number 7372,[63] but it does not necessarily mean it is illegal.

    In October 2003, U.S. patent #6630507 entitled "Cannabinoids as antioxidants and neuroprotectants" was assigned to "The United States Of America As Represented By The Department Of Health And Human Services." The patent was filed in April 1999 and listed as the inventors: Aidan J. Hampson, Julius Axelrod, and Maurizio Grimaldi, who all held positions at the National Institute of Mental Health (NIMH) in Bethesda, MD, which is part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). The patent mentions cannabidiol's ability as an antiepileptic, to lower intraocular pressure in the treatment of glaucoma, lack of toxicity or serious side effects in large acute doses, its neuroprotectant properties, its ability to prevent neurotoxicity mediated by NMDA, AMPA, or kainate receptors; its ability to attenuate glutamate toxicity, its ability to protect against cellular damage, its ability to protect brains from ischemic damage, its anxiolytic effect, and its superior antioxidant activity which can be used in the prophylaxis and treatment of oxidation associated diseases.[64]
    “ "Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosis, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • legal.... Patent... figure it out..

      Sentiment: Strong Buy

    • did you see this

    • This is a good start..

      Sentiment: Strong Buy

    • interesting.
      I never knew it was already patent.

      Sentiment: Strong Buy

    • assigned to "The United States Of America As Represented By The Department Of Health And Human Services.

      MJNA does not own this patent. You people know how to read?

    • “ "Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosis, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct in the brain, operative ischemia, traumatic hemorrhage (for example a hypovolemic stroke that can lead to CNS hypoxia or anoxia), spinal cord trauma, Down's syndrome, Crohn's disease, autoimmune diseases (e.g. rheumatoid arthritis or diabetes), cataract formation, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cellular apoptosis, radiation sickness, and others. The present invention is believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS, because of the ability of the cannabinoids to cross the blood brain barrier and exert their antioxidant effects in the brain. In particular embodiments, the pharmaceutical composition of the present invention is used for preventing, arresting, or treating neurological damage in Parkinson's disease, Alzheimer's disease and HIV dementia; autoimmune neurodegeneration of the type that can occur in encephalitis, and hypoxic or anoxic neuronal damage that can result from apnea, respiratory arrest or cardiac arrest, and anoxia caused by drowning, brain surgery or trauma (such as concussion or spinal cord shock)."[64] ”

      On November 17, 2011, the Federal Register published that the National Institutes of Health of the United States Department of Health and Human Services was "contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6,630,507" to the company KannaLife based in New York, for the development and sale of cannabinoid and cannabidiol based therapeutics for thetreatment of hepatic encephalopathy in humans.[65]

      Sentiment: Strong Buy

      • 1 Reply to gooforitt
      • On November 17, 2011, the Federal Register published that the National Institutes of Health of the United States Department of Health and Human Services was "contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6,630,507" to the company KannaLife based in New York, for the development and sale of cannabinoid and cannabidiol based therapeutics for the treatment of hepatic encephalopathy in humans.[65]

        +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

        http://en.wikipedia.org/wiki/KannaLife

        KannaLife
        From Wikipedia, the free encyclopedia
        KannaLife Sciences Inc. Corporate logo
        Type Private
        Industry Pharmaceutical
        Founded 2010
        Headquarters West Hills, New York
        Total assets Exclusive License of patent US 6630507
        Website http://kannalife.com
        KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507 “Cannabinoids as Antioxidants and Neuroprotectants."

        KannaLife Sciences Inc.is a late stage bio-pharmaceutical and phyto-medical company based in West Hills, NY and Doylestown, PA. KannaLife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.

        In 2011, the company was granted an Exclusive License[1] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507, “Cannabinoids as Antioxidants and Neuroprotectants."[2]

        KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[3] in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy, an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.
        ____________________________________________________________________________________

        http://www.kannalife.com/kannalife-sciences-announces-15m-series-a-financing-from-medical-marijuana-inc-and-cannavest/

        KannaLife Sciences Announces $1.5M Series A Financing From Medical Marijuana Inc. (OTC:MJNA) And CannaVest Corp. (OTC:FCLS)

        NEW YORK, March 7, 2013 — KannaLife Sciences, Inc. (“KannaLife”) the phyto-medical company that specializes in the research & development of pharmacological products derived from botanical sources, announced today the entry into Series A financing totaling $1.5 million.

        Sentiment: Strong Buy

 
MJNA
0.178-0.006(-3.37%)Apr 16 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.